Startups
ICONOVO AB is developing proprietary inhalation products for licensing. We have long experience and track record in the development of dry powder inhalers and offer a comprehensive range of devices to our clients. Our selection of device concepts for dry powder inhalation include a reservoir inhaler, a pre-metered inhaler, a capsule based inhaler and a single dose disposable inhaler. We can also provide formulation development, performance testing, documentation and a complete supply-chain.
Overview
Location
Sweden, Scania, Lund
Employees
11-50
Total raised
$2.56M
Founded date
2013
Funding Rounds 1
| Date | Series | Amount | Investors |
| Sign up to see | Sign up to see | Sign up to see | Sign up to see |
Mentions in press and media 6
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| May 21, 2024 | BioStock: Iconovo initiates development of inhaled obesity treatment | BioStock: Iconovo initiates development of inhaled obesity treatment Tue, May 21, 2024 08:15 CET Report this content Iconovo has filed a broad patent application for inhaled GLP-1 receptor agonists, used for the treatment of obesity and typ... |
| May 26, 2021 | ICONOVO AB (PUBL) Iconovo : communicates its new long-term strategy to the market | Iconovo AB (publ), which develops complete inhalation products for a global market, today communicates the opportunities that its new long-term strategy presents to the market. Investors, analysts, and media are invited to today's virtual c... |
| May 20, 2021 | Iconovo and Respiratorius sign agreement for development of inhalation product to treat COPD | Iconovo and Respiratorius sign agreement for development of inhalation product to treat COPD Thu, May 20, 2021 08:30 CET Iconovo AB (publ), which develops complete inhalation products for a global market, and Respiratorius AB (publ), which ... |
| Jun 22, 2017 | Term Sheet — Thursday, June 22 | CORPORATE INNOVATION TOUR This is the first of three stories in a series I’m calling “Corporate Innovation Tour.” Paid Content How can you protect what you can't see? From ExtraHop Most Fortune 500 incumbents follow a pattern: Stage 1: Dism... |
| Jun 22, 2017 | Iconovo Raises €2.3m in Funding | Iconovo, a Lund, Sweden-based developer of inhalers for drugs that treat conditions such as asthma and COPD, raised €2.3m in funding. The name of the backers were not disclosed. The company will use the funds to expand its offering to also ... |
Reviews 0
FAQ about Iconovo AB
When was Iconovo AB founded?
Iconovo AB was founded in 2013.
How much funding has Iconovo AB raised?
Iconovo AB has raised $2.56M in total across 1 funding round.
What has the press written about Iconovo AB?
Parsers VC has collected 6 articles mentioning Iconovo AB, among them “BioStock: Iconovo initiates development of inhaled obesity treatment” (May 21, 2024) and “ICONOVO AB (PUBL) Iconovo : communicates its new long-term strategy to the market” (May 26, 2021).
Is Iconovo AB still active?
Yes, Iconovo AB is active; its latest activity on Parsers VC dates from Sep 16, 2024.